Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis

Abstract

The usefulness of serum angiotensin-converting enzyme (sACE) for diagnosing sarcoidosis and determining the active status of sarcoidosis has been reported with varying outcomes. On the basis of the majority of published data, we conducted a meta-analysis to calculate the overall predictive accuracy of sACE in sarcoidosis disease and the active status of sarcoidosis. The inclusion of related research listed in Web of Science, PubMed, Scopus, and other literature databases was assessed. SROC curves were generated to characterize the overall test results after data on sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were combined. Publication bias was identified using Deeks’ funnel plot. Thirty-five publications with 8645 subjects met the inclusion criteria. The following are summary estimates of sACE diagnostic performance for sarcoidosis: sensitivity, 60% (95% confidence interval (CI), 52–68%); specificity, 93% (95% CI, 88–96%); PLR, 8.4 (95% CI, 5.3–13.3); NLR, 0.43 (95% CI, 0.36–0.52); and DOR, 19 (95% CI, 12–31). The area under the SROC curve (AUC) was 0.84 (95% CI, 0.80–0.87). Summary estimates for predicting the active status of sarcoidosis were as follows: sensitivity, 0.76 (95% CI, 0.61–0.87); specificity, 0.80 (95% CI, 0.64–0.90); PLR, 3.9 (95% CI, 2.1–7.3); NLR, 0.29 (95% CI, 0.17–0.49); and DOR, 13 (95% CI, 6–31). The AUC was 0.85 (95% CI, 0.82–0.88). There was no evidence of publication bias. Our meta-analysis suggests that measuring the sACE may assist in the diagnosis of sarcoidosis and predicting the active status of sarcoidosis, but the interpretation of the sACE results should be with caution. Future studies should validate our results.

التنبؤ المبكر بالاعتلال الكلوي لمرضى عراقين مصابين بالسكري النوع الثاني بدلالة تقييم بعض العوامل البيوكيمائية ذات الصلة

“…These cells are a result of cytokins IL-6, and MCP1 inflammation induced product connective tissue growth factor (CTGF) related with fibrosis 38 . Connective tissue growth factor (CTGF) expression is modest in healthy adult kidneys but is significantly elevated in a number of renal disorders, where it plays an important role in the development of glomerular and tubular interstitial fibrosis involved in cell migration, proliferation and differentiation, connective tissue growth factor (CTGF) acts either directly to promote fibrosis 39 .Our current study demonstrated an increase in connective tissue growth factor, which indicates glomerular and tubular damage and fibrosis in diabetic patients. This finding is consistent with Koszegi, S., et al who found elevated serum connective tissue growth factor (CTGF) expression as a strong predictor of renal fibrosis 40 .…”

Differential diagnosis of a local form of granulomatosis with polyangiitis: nasal cavity and paranasal sinuses lesions (part 1)

“…АНФ, РФ и гипергаммаглобулинемия встречались у трети больных саркоидозом [28]. Высокий уровень ангиотензипревращающего фермента (АПФ) -важный диагностический критерий, позволяющий дифференцировать поражение ПППН при саркоидозе от локальной формы ГПА [57]. Морфологическим субстратом саркоидоза является неказеозная гигантоклеточная эпителиоидная гранулема, представляющая собой компактное скопление мононуклеарных фагоцитовмакрофагов и эпителиоидных клеток [52].…”

Liver biopsy as a useful diagnostic tool for hepatic sarcoidosis: A case report

“…There are several biomarkers used for sarcoidosis (3,4). Angiotensin-converting enzyme (ACE) is expressed in several human tissues, including the lungs, as a membrane-bound acid glycoprotein mostly produced by activated alveolar macrophages, and ACE converts angiotensin I to angiotensin II (3,5).…”